UNKNOWN

Anticoagulation in Gastroesophageal Varices and JAK2 Mutation

Anticoagulation Treatment of Patients With Gastroesophageal Varices and JAK2 V617 Mutation

NCT04527666•Shanghai Zhongshan Hospital

Summary

Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, may lead to gastroesophageal varices. The quality of life, morbidity, and mortality of MPN patients mainly depend on disease-related symptoms, thromboembolic and hemorrhagic complications. Previous studies have shown that JAK2 V617F has a prominent role in vascular risk and MPN-associated gastroesophageal varices. The aim of this study is to evaluate the efficacy of anticoagulation in patients with JAK2 mutation and gastroesophageal varices.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Male or female patients aged 18-75
•diagnosed as portal hypertension by contrast-enhanced computed tomography
•diagnosed as JAK2 positive

Exclusion Criteria

•not had portal contrast-enhanced computed tomography
•not had JAK2 mutation test
•other factors judged by the investigator that may affect the safety of the subject or the compliance of the trial. Such as serious illnesses (including mental illness) that require combined treatment, serious laboratory abnormalities, or other family or social factors

Key Dates

Start Date

October 1, 2020

Primary Completion Date

September 30, 2021

Completion Date

September 30, 2022

Last Updated

August 27, 2020

Enrollment

40

ESTIMATED participants

Conditions

Gastroesophageal VaricesJAK2 MutationMyeloproliferative Neoplasm

Interventions

Anticoagulation Agents

DRUG

Contacts

Xiaoquan HUANG, Ph.D

CONTACT

18801733835 huang.xiaoquan@zs-hospital.sh.cn

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424

AML (Acute Myelogenous Leukemia)Acute Lymphoid Leukemia (ALL)+9 more

View study

RECRUITINGPHASE1/PHASE2

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

NCT06523556

Atypical Chronic Myeloid LeukemiaChronic Myelomonocytic Leukemia

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 27, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

+6 more

View study

RECRUITINGPHASE1